文献速递其他结缔组织病

反映不同致病过程的血清生物标志物在系统性硬化症相关间质性肺病中的性能

Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

研究纳入225例系统性硬化症(SSc)患者,用ELISA检测基线及随访血清中KL-6、SP-D、CCL18、YKL-40和MMP-7水平,按2022年ATS/ERS/JRS/ALAT指南定义进展性间质性肺病(ILD)。五种标志物均与SSc-ILD的存在独立相关,联合KL-6与SP-D可能作为识别ILD进展风险患者的生物标志物。

要点

  • KL-6、SP-D、CCL18、YKL-40和MMP-7均与SSc-ILD的存在独立相关。
  • 包含所有候选标志物的机器学习模型分类有无ILD的准确率为85%。
  • 基线KL-6或SP-D升高增加未来SSc-ILD进展的比值比,联合KL-6与SP-D性能优于单独使用。

核心结论

  • 所有候选标志物作为SSc-ILD的诊断生物标志物均表现良好。
  • 联合KL-6与SP-D可能作为识别有ILD进展风险的SSc患者的生物标志物。

研究设计与样本

  • 研究分析225例SSc患者的基线和随访血清样本,采用ELISA检测。
  • 进展性ILD根据2022年ATS/ERS/JRS/ALAT指南定义。
  • 统计分析使用线性混合模型和随机森林模型。

主要发现

  • 血清KL-6(均差35.67,95%CI 22.44-48.89,P<0.01)与SSc-ILD的存在独立相关。
  • 血清SP-D(均差81.13,95%CI 28.46-133.79,P<0.01)与SSc-ILD的存在独立相关。
  • 血清CCL18(均差17.07,95%CI 6.36-27.77,P<0.01)与SSc-ILD的存在独立相关。
  • 血清YKL-40(均差22.81,95%CI 7.19-38.44,P<0.01)与SSc-ILD的存在独立相关。
  • 血清MMP-7(均差2.84,95%CI 0.88-4.80,P<0.01)与SSc-ILD的存在独立相关。

关键数值与推荐

  • 包含所有候选标志物的机器学习模型分类有无ILD的准确率为85%。
  • KL-6与SP-D联合与SSc-ILD的存在相关(0.77,95%CI 0.53-1.00,P'<0.01)。
  • KL-6与SP-D联合与SSc-ILD既往进展相关(OR 1.28,95%CI 1.01-1.61,P'=0.047)。
  • 基线KL-6较高增加未来SSc-ILD进展的比值比(OR 3.70,95%CI 1.52-9.03,P<0.01),独立于其他常规危险因素。
  • 基线SP-D较高增加未来SSc-ILD进展的比值比(OR 2.00,95%CI 1.06-3.78,P=0.03),独立于其他常规危险因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) is the leading cause of mortality in SSc. Novel biomarkers are crucial to improve outcomes in SSc-ILD. We aimed to compare the performance of potential serum biomarkers of SSc-ILD that reflect different pathogenic processes: KL-6 and SP-D (epithelial injury), CCL18 (type 2 immune response), YKL-40 (endothelial injury and matrix remodelling) and MMP-7 (ECM remodelling). METHODS: Baseline and follow-up serum samples from 225 SSc patients were analysed by ELISA. Progressive ILD was defined according to the 2022-ATS/ERS/JRS/ALAT guidelines. Linear mixed models and random forest models were used for statistical analyses. RESULTS: Serum levels of KL-6 [MD 35.67 (95% CI 22.44-48.89, P < 0.01)], SP-D [81.13 (28.46-133.79, P < 0.01)], CCL18 [17.07 (6.36-27.77, P < 0.01)], YKL-40 [22.81 (7.19-38.44, P < 0.01)] and MMP-7 [2.84 (0.88-4.80, P < 0.01)] were independently associated with the presence of SSc-ILD. A machine-learning model including all candidates classified patients with or without ILD with an accuracy of 85%. The combination of KL-6 and SP-D was associated with the presence [0.77 (0.53-1.00, P' <0.01)] and previous progression of SSc-ILD [OR 1.28 (1.01-1.61, P' =0.047)]. Higher baseline levels of KL-6 [OR 3.70 (1.52-9.03, P < 0.01)] or SP-D [OR 2.00 (1.06-3.78, P = 0.03)] increased the odds of future SSc-ILD progression, independent of other conventional risk factors, and the combination of KL-6 and SP-D [1.109 (0.665-1.554, P < 0.01)] showed improved performance compared with KL-6 and SP-D alone. CONCLUSION: All candidates performed well as diagnostic biomarkers for SSc-ILD. The combination of KL-6 and SP-D might serve as biomarker for the identification of SSc patients at risk of ILD progression.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Györfi AH, Filla T, Dickel N, et al. Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2024. PMID: 37421394. doi:10.1093/rheumatology/kead332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。